These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17584140)

  • 1. Strategies for design of non peptide CCK1R agonist/antagonist ligands.
    García-López MT; González-Muñiz R; Martín-Martínez M; Herranz R
    Curr Top Med Chem; 2007; 7(12):1180-94. PubMed ID: 17584140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of CCKRs and SAR studies of peptidic analog ligands.
    Noble F
    Curr Top Med Chem; 2007; 7(12):1173-9. PubMed ID: 17584139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
    Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
    J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.
    Berna MJ; Tapia JA; Sancho V; Jensen RT
    Curr Opin Pharmacol; 2007 Dec; 7(6):583-92. PubMed ID: 17997137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain.
    Hruby VJ; Agnes RS; Davis P; Ma SW; Lee YS; Vanderah TW; Lai J; Porreca F
    Life Sci; 2003 Jun; 73(6):699-704. PubMed ID: 12801591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
    Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
    Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structure-activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold.
    Bartolomé-Nebreda JM; García-López MT; González-Muñiz R; Cenarruzabeitia E; Latorre M; Del Río J; Herranz R
    J Med Chem; 2001 Nov; 44(24):4196-206. PubMed ID: 11708921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validated ligand binding sites in CCK receptors. next step: computer-aided design of novel CCK ligands.
    Tikhonova IG; Marco E; Lahlou-Archer E; Langer I; Foucaud M; Maigret B; Fourmy D
    Curr Top Med Chem; 2007; 7(12):1243-7. PubMed ID: 17584146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor.
    Cawston EE; Lam PC; Harikumar KG; Dong M; Ball AM; Augustine ML; Akgün E; Portoghese PS; Orry A; Abagyan R; Sexton PM; Miller LJ
    J Biol Chem; 2012 May; 287(22):18618-35. PubMed ID: 22467877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists?
    Patel S; Chapman KL; Smith AJ; Bailey I; Freedman SB
    Regul Pept; 1996 Aug; 65(1):29-35. PubMed ID: 8876033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
    Agnes RS; Ying J; Kövér KE; Lee YS; Davis P; Ma SW; Badghisi H; Porreca F; Lai J; Hruby VJ
    Peptides; 2008 Aug; 29(8):1413-23. PubMed ID: 18502541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor.
    Desai AJ; Mechin I; Nagarajan K; Valant C; Wootten D; Lam PCH; Orry A; Abagyan R; Nair A; Sexton PM; Christopoulos A; Miller LJ
    Mol Pharmacol; 2019 Mar; 95(3):245-259. PubMed ID: 30591538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Dipeptoids": from the chemical structure of the endogenous peptide to the design of peptidomimetics.
    Martín-Martínez M; Patiño-Molina R; García-López MT; González-Muñiz R
    Mini Rev Med Chem; 2004 Aug; 4(6):669-80. PubMed ID: 15279601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
    Martín-Martínez M; Bartolomé-Nebreda JM; Gómez-Monterrey I; González-Muñiz R; García-López MT; Ballaz S; Barber A; Fortuño A; Del Río J; Herranz R
    J Med Chem; 1997 Oct; 40(21):3402-7. PubMed ID: 9341915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor.
    Harikumar KG; Pinon DI; Wessels WS; Prendergast FG; Miller LJ
    J Biol Chem; 2002 May; 277(21):18552-60. PubMed ID: 11893747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.
    Berna MJ; Jensen RT
    Curr Top Med Chem; 2007; 7(12):1211-31. PubMed ID: 17584143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.
    Fourmy D; Escrieut C; Archer E; Galès C; Gigoux V; Maigret B; Moroder L; Silvente-Poirot S; Martinez J; Fehrentz JA; Pradayrol L
    Pharmacol Toxicol; 2002 Dec; 91(6):313-20. PubMed ID: 12688374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies.
    Galés C; Poirot M; Taillefer J; Maigret B; Martinez J; Moroder L; Escrieut C; Pradayrol L; Fourmy D; Silvente-Poirot S
    Mol Pharmacol; 2003 May; 63(5):973-82. PubMed ID: 12695525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
    Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholecystokinin-B receptor ligands of the dipeptoid series act as agonists on rat stomach histidine decarboxylase.
    Ding XQ; Chen D; Håkanson R
    Gastroenterology; 1995 Oct; 109(4):1181-7. PubMed ID: 7557084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.